Somatic gene therapy for a neurodegenerative disease using microencapsulated recombinant cells

Experimental Neurology

Volumn 166, Issue 2, 2000, Pages 276-286

  Ross, C J D ^a   Ralph, M ^b   Chang, P L ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alginate; Behavioral abnormality; Central nervous system; Circadian rhythm; Immunoisolation; Lysosomal storage disease; Mucopolysaccharidosis VII; glucuronidase

Indexed keywords

ALPHA GALACTOSIDASE; BETA GLUCURONIDASE; BETA N ACETYLHEXOSAMINIDASE; GLYCOSAMINOGLYCAN; LYSOSOME ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOENGINEERING; BLOOD BRAIN BARRIER; CELL LINE; CIRCADIAN RHYTHM; CONTROLLED STUDY; ENZYME DEFICIENCY; GENE THERAPY; LYSOSOME STORAGE DISEASE; MICROENCAPSULATION; MOUSE; MUCOPOLYSACCHARIDOSIS TYPE 7; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0033670210     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2000.7531     Document Type: Article

References (55)

1. The metabolic basis of inherited disease
2. Evaluation of reaction of primate brain to grafted PC12 cells
3. Long-term enhanced chromaffin cell survival and behavioral recovery in hemiparkinsonian rats with co-grafted polymer-encapsulated human NGF-secreting cells
4. Dose-dependent doxycycline-mediated adrenocorticotropic hormone secretion from encapsulated Tet-on proopiomelanocortin Neuro2A cells in the subarachnoid space
5. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease
6. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients
7. Delivery of recombinant gene products to the central nervous system with nonautologous cells in alginate microcapsules
8. Nonautologous somatic gene therapy
9. Lysosomal storage diseases
10. Beta glucuronidase deficiency: Report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis
11. Behavioral abnormalities in a murine model of a human lysosomal storage disease
12. Behavioral consequences of bone marrow transplantation in the treatment of murine mucopolysaccharidosis type VII
13. Syngeneic bone marrow transplantation reduces the hearing loss associated with murine mucopolysaccharidosis type VII
14. Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency
15. A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase-deficient mice
16. A single-base-pair deletion in the beta-glucuronidase gene accounts for the phenotype of murine mucopolysaccharidosis type VII
17. Neuropathology of murine mucopolysaccharidosis type VII
18. Continuous systemic secretion of a lysosomal enzyme by genetically modified mouse skin fibroblasts
19. Murine mucopolysaccharidosis type VII: Long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation
20. Central nervous system cell transplantation: A novel therapy for storage diseases?
21. Somatic gene therapy of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells
22. Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates
23. Enzyme replacement with recombinant beta-glucuronidase in the newborn mucopolysaccharidosis type VII mouse
24. Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function
25. Enzyme replacement in murine mucopolysaccharidosis type VII: Neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy
26. Systemic hyperosmolality improves beta-glucuronidase distribution and pathology in murine MPS VII brain following intraventricular gene transfer
27. Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain
28. Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase
29. Herpes-virus vector gene transfer and expression of beta-glucuronidase in the central nervous system of MPS VII mice
30. Increased susceptibility to the pathogenic effects of wild-type and recombinant herpesviruses in MPS VII mice compared to normal siblings
31. Adenovirus-mediated gene transfer and expression of human beta-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice
32. Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice
33. Cross-correction of betaglucuronidase deficiency by retroviral vector-mediated gene transfer
34. Large scale purification of phosphorylated recombinant human beta-glucuronidase from overexpressing mouse L cells
35. Expression of human factor IX by microencapsulated recombinant fibroblasts
36. Transplanted suprachiasmatic nucleus determines circadian period
37. Beta-glucuronidase deficiency mucopolysaccharidosis: Methods for enzymatic diagnosis
38. Protein measurement with the folin phenol reagent
39. Interendothelial junctional changes underlie the developmental 'tightening' of the blood-brain barrier
40. Extensive beta-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain
41. Turnover of murine beta-glucuronidase. Comparison among liver, kidney, and spleen and between lysosomes and microsomes
42. Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus
43. Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice
44. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease
45. Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector
46. Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice
47. AAVant-garde gene therapy
48. Long-term functional assessment of encapsulated cells transfected with Tet-On system
49. Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum
50. Transplantation of a polymer-encapsulated cell line genetically engineered to release NGF
51. Polymer-encapsulated Schwannoma cells expressing human nerve growth factor promote the survival of cholinergic neurons after a fimbria-fornix transection
52. Behavioral recovery following intrastriatal implantation of microencapsulated PC12 cells
53. Transplantation of microencapsulated bovine chromaffin cells reduces lesion-induced rotational asymmetry in rats
54. Long-term cross-species brain transplantation of a polymer-encapsulated dopamine-secreting cell line
55. Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts